1. The Leukaemias - FAR TOO MANY CELLS; FAR TOO MANY VOWELS - toby m robins

2. Leukaemia may be Acute or Chronic

3. and it may be Lymphoblastic or Myeloid

4. Put that all together and you get Acute lymphoblastic leukaemia Acute myeloid leukaemia Chronic lymphoblastic leukaemia Chronic myeloid leukaemia

5. For each, we will briefly cover Definition Epidemiology Aetiology Pathogenesis Clinical features Investigations Management Prognosis

6. but first What exactly IS leukaemia?

7. Leukaemia is Production

8. of abnormal WBCs

9. at an excessive rate

10. +/- reduced destruction

11. i.e. it is malignancy of the leukocytes

12. and it is clonal - ie all the malignant cells have a recent common ancestor

13. it is classified according to 1. the dominant cell type and 2. the duration from onset to death

14. Chronic leukaemia Untreated, exceeds one year (with gradual onset of symptoms)

15. Acute leukaemia Untreated, death ensues within a few months

16. The acute ones ALL (acute lymphoblastic leukaemia) AML (acute myeloid leukaemia)

17. firstly Acute Myeloid Leukaemia

18. Definition of AML Neoplastic proliferation of myeloid blast cells

19. Myeloid blast cells explained Mature blood cells are derived originally from pluripotent stem cells

20. Meyloid blast cells explained Pluripotent stem cells then divide and differentiate either into myeloid stem cells or lymphoid stem cells M L

21. Myeloid blast cells explained Lymphoid stem cells make lymphocytes Myeloid stem cells make all the other blood cells

22. SEW

23. There’s more than ONE kind of AML Morphologically, there are seven and a half: – M1 = undifferentiated blast cells – M2 = myeloblastic – M3 = promyelocytic – M4 = myelomonocytic – M4 eo = myelomonocytic with dysplastic eosinophils – M5 = monocytic – M6 = erythroleukaemia – M7 = megakaryoblastic leukaemia

24. Epidemiology 70-year-old, male, Eastern European Jews

25. Aetiology ?

26. All implicated have been – Heredity – Radiation – Mutagenic drugs – Chemical & other occupational exposures – secondary to previous chronic leukaemia or myelodysplasia

27. Clinical features Symptoms and signs are a result of 3 things: – 1. Marrow failure – 2. Leukaemic infiltration of tissues – 3. Consitutional upset

28. Symptoms relating to marrow failure Infection Bleeding or easy bruising symptoms of anaemia - shortness of breath, etc

29. Symptoms relating to leukaemic infiltration Symptoms of a mass lesion (rarer, since leukaemias by definition tend not to form masses) – bone – breast, uterus, ovary – cranial or spinal dura – GI tract – lung or mediastinum – prostate

30. Symptoms relating to constitutional upset Malaise Fatigue Weakness Fever or sweats Anorexia or weight loss Non-specific cough

31. Signs relating to marrow failure Evidence of infection Signs of anaemia Purpura or signs of bruising/bleeding – including retinal haemorrhages

32. Signs relating to leukaemic infiltration Hepatosplenomegaly Lymphadenopathy Sternal tenderness Thymic mass Gingival hypertrophy

33. Signs relating to constitutional upset Fever

34. Investigations FBC Blood film U&Es LFTs coagulation (especially for the DIC of M3) Bone marrow examination cell markers and molecular studies (eg of marrow cells)

35. FBC Anaemia Neutropenia Thrombocytopenia

36. Blood film Blast cells that contain – granules – Auer rods

37. U&Es, LFTs The following are occasionally increased – calcium – urea – LFTs

38. Bone marrow examination Blast cells constituting > 20% of the bone marrow cells is diagnostic

39. Cell markers, molecular studies Flow cytometry (immunophenotyping) may aid in morphological (ie appearance-based) diagnosis and may add further prognostic information Karyotyping, FISH, and PCR may confirm diagnosis (eg acute promyelocytic leukamia; =M3), + may add information not otherwise obtainable

40. Management includes Intensive chemotherapy Bone marrow transplant Supportive care

41. Chemotherapy Divided into 3 phases – 1. Remission induction – 2. Remission consolidation – 3. Remission maintenance

42. 1. Chemotherapy for remission induction Complete remission (CR) – full recovery of haematopoiesis, with – blasts accounting for < 5% of bone marrow cells Involves mainly – anthracyclines – cytosine arabinoside

43. Why have they chosen these drugs? Anthracyclines – because AML is like cycling a “myel” and a half with anthrax Cytosine arabinoside – think “sight-o-seen arabocide” – because some (ignorant,misinformed,prejudiced) people because think an Arab that comes within a “myel” radius should be shot on sight – sorry, Tarik, no offence :)

44. 2. Chemotherapy for remission consolidation Involves similar chemotherapy to that of remission induction

45. 3. Chemotherapy for remission maintenance Treatment is continued for 2 years in ALL, but for a much shorter time in AML

46. Bone marrow transplant (BMT) Suitable marrow may be – allogeneic (from histocompatible siblings or unrelated donors) – syngeneic (from an identical twin) – autologous

47. BMT continued Used increasingly as a form of consolidation Use depends on the pt’s age – the elderly develop more complications

48. BMT continued Marrow is infused intravenously to “rescue” the pt from otherwise supralethal chemoradiotherapy Enables destruction of (almost) all leukaemic cells and the entire immune system with eg cyclophosphamide plus total body irradiation

49. Why use cyclophosphamide? ‘cause you midas well make phossels out of all those nasty leukaemia cells in one foul swoop (cycle) A FOUL SWOOP

50. BMT continued To reduce graft vs host effect – cyclosporin +/- – methotrexate Complications – graft vs host disease – infections (commonly CMV) – veno-occlusive disease – relapse of leukaemia

51. Supportive treatment Blood transfusion for anaemia Platelet transfusion for thrombocytopenic bleeding Prompt antibiotic treatment, and prevention, of infections Hygeine

52. Prognosis 70% achieve complete remission lasting (on average) 12 months Long-term survival (~ 50%)

53. Secondly Acute Lymphoblastic Leukaemia

54. Definition Neoplastic proliferation of lymphoblasts

55. Types of ALL Common – phenotypically pre-B lymphocytes – 75% of cases T-cell B-cell Null-cell

56. Aetiology as for AML

57. Epidemiology (Common ALL) 4-year-olds

58. Epidemiology (T-cell ALL) Adolescent males

59. Clinical features as for AML

60. Investigations As for AML Blood film shows –small blasts with –a high nuclear-cytoplasmic ratio